Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 13

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 13
---
LS and Kadimastem prior to the closing of the Merger expects to, and NLS following the closing of the Merger may, incur significant costs in connection with the Merger. |

| ● | Lawsuits may be commenced seeking to enjoin or prevent the Merger or seeking other relief which may delay or prevent the completion of the Merger and result in NLS or Kadimastem incurring substantial costs. |

| ● | The unaudited pro forma condensed consolidated financial information incorporated by reference in this prospectus is presented for illustrative purposes only and may not be reflective of what the operating results and financial condition of NLS for the historical periods presented would have been or may be following consummation of the Merger. |

| ● | If the Merger’s benefits do not meet the expectations of investors, shareholders or financial analysts, the market price of securities may decline. |

| ● | Even if the Merger is completed, there is no guarantee that any proceeds will be paid to NLS shareholders under the CVR Agreement. |

| ● | Following the Merger, NLS intends to shift its business focus to developing and manufacturing “off-the-shelf”, allogenic, proprietary cell products, which may not be successful. |

| ● | Following the Merger, NLS may be unable to integrate successfully and realize the anticipated benefits of the Merger. |

| ● | Following the Merger, NLS’s business strategy will depend heavily on advancing and commercializing its pipeline products. However, NLS’s research and development efforts are subject to substantial risk, as drug development requires significant investment and faces inherent uncertainties. |

| ● | Kadimastem has incurred significant operating losses since Kadimastem’s inception and anticipate that Kadimastem will incur continued losses for the foreseeable future. |

| ● | Kadimastem cannot give any assurance that any of its drug substances and product candidates will receive regulatory approval, which is necessary before they can be commercialized. |

| ● | Kadimastem has not generated revenue from any product candidate and may never be profitable. |

| ● | The results of Kadimastem’s clinical trials may not support its product candidates’ claims or any additional claims Kadimastem may seek for its drug substances and product candidates and its clinical trials may result in the discovery of adverse side effects. |

<div align='center'>5</div>

| ● | Kadimastem will need to obtain FDA approval of any proposed names for its drug substances